Literature DB >> 22290952

In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.

Valentina Salas1, F Javier Pastor, Enrique Calvo, Eduardo Alvarez, Deanna A Sutton, Emilio Mayayo, Anette W Fothergill, Michael G Rinaldi, Josep Guarro.   

Abstract

The in vitro susceptibility of 17 strains of Mucor circinelloides to amphotericin B and posaconazole was ascertained by using broth microdilution and disk diffusion methods and by determining the minimal fungicidal concentration (MFC). We evaluated the efficacy of posaconazole at 40 mg/kg of body weight/day and amphotericin B at 0.8 mg/kg/day in a neutropenic murine model of disseminated infection by M. circinelloides by using 6 different strains tested previously in vitro. In general, most of the posaconazole MICs were within the range of susceptibility or intermediate susceptibility, while the small inhibition zone diameters (IZDs) were indicative of nonsusceptibility for all isolates tested. The MFCs were ≥ 3 dilutions higher than the corresponding MICs. In contrast, amphotericin B showed good activity against all of the strains tested regardless of the method used. The in vivo studies demonstrated that amphotericin B was effective in prolonging survival and reducing the fungal load. Posaconazole showed poor in vivo efficacy with no correlation with the MIC values. The results suggested that posaconazole should be used with caution in the treatment of infections caused by Mucor circinelloides or by strains of Mucor not identified to the species level.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290952      PMCID: PMC3346623          DOI: 10.1128/AAC.05956-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR-restriction fragment-length polymorphism method.

Authors:  J Larché; M Machouart; K Burton; J Collomb; M F Biava; A Gérard; B Fortier
Journal:  Clin Infect Dis       Date:  2005-11-01       Impact factor: 9.079

3.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

Review 4.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Two new species of Mucor from clinical samples.

Authors:  Eduardo Alvarez; Josep Cano; Alberto M Stchigel; Deanna A Sutton; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Med Mycol       Date:  2010-07-22       Impact factor: 4.076

7.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

8.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 9.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

10.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

View more
  18 in total

1.  Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors:  Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Authors:  A Espinel-Ingroff; A Chakrabarti; A Chowdhary; S Cordoba; E Dannaoui; P Dufresne; A Fothergill; M Ghannoum; G M Gonzalez; J Guarro; S Kidd; C Lass-Flörl; J F Meis; T Pelaez; A M Tortorano; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.

Authors:  Bianca Schulze; Günter Rambach; Volker U Schwartze; Kerstin Voigt; Katja Schubert; Cornelia Speth; Ilse D Jacobsen
Journal:  Virulence       Date:  2017-08-24       Impact factor: 5.882

Review 5.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Virulence and Resistance to Antifungal Therapies of Scopulariopsis Species.

Authors:  Katihuska Paredes; Javier Capilla; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 8.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

9.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

10.  Hyperthermia sensitizes Rhizopus oryzae to posaconazole and itraconazole action through apoptosis.

Authors:  Fazal Shirazi; Michael A Pontikos; Thomas J Walsh; Nathaniel Albert; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.